Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close.
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's commercial success and management's execution in ex vivo gene editing. Casgevy's Q2 sales grew 78% sequentially, reinforcing its blockbuster potential despite market skepticism and slow initial uptake. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, but clinical impact appears distant.
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs.
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -2.19% change compared to its last close.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts
CRISPR Therapeutics NASDAQ: CRSP CEO Sam Kulkarni outlined the company's commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026.
CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case
CRISPR Therapeutics transitioned from speculative biotech to commercial stage with FDA approval of CASGEVY, validating its CRISPR/Cas9 platform. CRSP's pipeline targets multi-billion-dollar markets in cardiovascular, autoimmune, oncology, and diabetes, supported by a robust IP portfolio and major pharma partnerships. Current $5.6B market cap and $1.78B net cash position offer acquisition appeal, but most pipeline assets remain early stage and execution risks persist.
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.
